Comparison of disability level between Early and Late Onset Parkinson's Disease using WHODAS 2

Imagem de Miniatura
Arquivos
art_NASCIMENTO_Comparison_of_disability_level_between_Early_and_Late_2023.PDF (512.19 KB)
Citações na Scopus
1
Tipo de produção
article
Data de publicação
2023
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
FRONTIERS MEDIA SA
Autores
NASCIMENTO, Isaira Almeida Pereira da Silva
NOBREGA, Katia Cirilo Costa
SOUZA, Bruno Rafael Antunes
BARONE, Isabela Carneiro
HELENE, Andre Frazao
Citação
FRONTIERS IN NEUROLOGY, v.14, article ID 1281537, 8p, 2023
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Background: Parkinson's disease (PD) is a degenerative neurological disorder that usually affects people over the age of 60. However, 10%-20% of patients have an early onset of PD (EOPD).Objectives: To compare disability levels according to the World Health Organization Disability Assessment Schedule 2.0 (WHODAS-2) between people with EOPD and those with late-onset PD (LOPD).Methods: We conducted a cross-sectional study with 95 EOPD patients (mean-age 44.51 +/- 4.63, H&Y 1.93 +/- 0.93) and 255 LOPD patients (mean-age 63.01 +/- 7.99, H&Y 2.02 +/- 0.95). Demographic information, clinical characteristics, cognitive evaluation by Telephone-Montreal-Cognitive-Assessment (T-MoCA), functionality self-evaluation by WHODAS-2 and the Unified-Parkinson's-Disease-Rating-Scale (MDS-UPDRS), parts I and II, were documented for each patient by an individual remote interview.Results: Analysis showed a statistically significant difference between EOPD and LOPD in two domains of WHODAS-2 only: cognition (Z-adjusted = 2.60; p-value adjusted <0.009) and activities of daily living related to work/school (Z-adjusted = 2.34; p-value adjusted <0.01). T-MoCA scores confirmed more impaired cognition capacity in LOPD (Z-adjusted = 2.42; p-value adjusted <0.01). The two groups had no significant differences in levodopa daily dosage, Hoehn and Yahr (H&Y) stages, disease time duration, and MDS-UPDRS I and II scores.Conclusion: People living with EOPD face similar disability levels as those with LOPD, except for cognition, where LOPD patients exhibited higher levels of disability than EOPD and for work activities where the EOPD exhibited higher levels of disability than LODP. These results highlight the challenges faced by people with EOPD in interacting with society and living with the disease for a longer time. The WHODAS-2 can be a useful tool to assess disability and tailor interventions for people with PD of different age groups.
Palavras-chave
Parkinson's disease, early onset, disability, cognition, WHODAS-2
URI
https://observatorio.fm.usp.br/handle/OPI/57392
Referências
  1. Ascherio A, 2016, LANCET NEUROL, V15, P1255, DOI 10.1016/S1474-4422(16)30230-7
  2. Becker D, 2022, PARKINSONS DIS-US, V2022, DOI 10.1155/2022/6233835
  3. Bhidayasiri R, 2020, PARKINSONISM RELAT D, V72, P82, DOI 10.1016/j.parkreldis.2020.02.013
  4. Camerucci E, 2021, J PARKINSON DIS, V11, P1197, DOI 10.3233/JPD-202464
  5. Cools CI, 2020, J PARKINSON DIS, V10, P1261, DOI 10.3233/JPD-201999
  6. Erkkinen MG, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a033118
  7. Garin O, 2010, HEALTH QUAL LIFE OUT, V8, DOI 10.1186/1477-7525-8-51
  8. Goetz CG, 2008, MOVEMENT DISORD, V23, P2129, DOI 10.1002/mds.22340
  9. Harrison MB, 2009, MOVEMENT DISORD, V24, P224, DOI 10.1002/mds.22335
  10. HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427
  11. Horváth K, 2017, MOVEMENT DISORD, V32, P789, DOI 10.1002/mds.26960
  12. Katz MJ, 2021, ALZH DEMENT-DADM, V13, DOI 10.1002/dad2.12144
  13. Knipe MDW, 2011, MOVEMENT DISORD, V26, P2011, DOI 10.1002/mds.23763
  14. Mehanna R, 2022, MOV DISORD CLIN PRAC, V9, P869, DOI 10.1002/mdc3.13523
  15. Mehanna R, 2019, PARKINSONISM RELAT D, V65, P39, DOI 10.1016/j.parkreldis.2019.06.001
  16. Mehanna R, 2014, PARKINSONISM RELAT D, V20, P530, DOI 10.1016/j.parkreldis.2014.02.013
  17. Murman Daniel L., 2015, Seminars in Hearing, V36, P111, DOI 10.1055/s-0035-1555115
  18. Murphy R, 2013, IRISH J MED SCI, V182, P415, DOI 10.1007/s11845-013-0902-5
  19. Ou RW, 2021, J NEUROL, V268, P1876, DOI 10.1007/s00415-020-10333-4
  20. Pagano G, 2016, NEUROLOGY, V86, P1400, DOI 10.1212/WNL.0000000000002461
  21. Parashos SA, 2015, J PARKINSON DIS, V5, P67, DOI 10.3233/JPD-140405
  22. Riboldi GM, 2022, J PARKINSON DIS, V12, P1, DOI 10.3233/JPD-212815
  23. Schrag A, 2000, BRIT MED J, V321, P21, DOI 10.1136/bmj.321.7252.21
  24. Schrag A, 2003, MOVEMENT DISORD, V18, P1250, DOI 10.1002/mds.10527
  25. Schrag A, 2006, MOVEMENT DISORD, V21, P1839, DOI 10.1002/mds.21030
  26. Serrano-Dueñas M, 2020, CLIN NEUROL NEUROSUR, V194, DOI 10.1016/j.clineuro.2020.105872
  27. Tomlinson CL, 2010, MOVEMENT DISORD, V25, P2649, DOI 10.1002/mds.23429
  28. van der Eijk M, 2013, PARKINSONISM RELAT D, V19, P923, DOI 10.1016/j.parkreldis.2013.04.022
  29. Vela-Desojo L, 2020, J PARKINSON DIS, V10, P1621, DOI 10.3233/JPD-202066
  30. Wickremaratchi MM, 2011, MOVEMENT DISORD, V26, P457, DOI 10.1002/mds.23469
  31. World Health Organization, 2017, International classification of functioning, disability and health
  32. Ylikotila P, 2015, PARKINSONISM RELAT D, V21, P938, DOI 10.1016/j.parkreldis.2015.06.003

Coleções
Artigos e Materiais de Revistas Científicas - FM/MFT
Carregar mais